Search results for "clinical research"

showing 10 items of 474 documents

FRI0265 Selexipag in Raynaud's Phenomenon Secondary To Systemic Sclerosis: A Randomised, Placebo-Controlled, Phase II Study

2016

Background Raynaud9s phenomenon (RP) occurs in >95% of patients (pts) with systemic sclerosis (SSc) and contributes to digital ischaemia that may lead to digital ulcers (DUs) and gangrene.1,2 Empirical treatment of SSc-associated RP includes oral vasodilators, particularly calcium channel blockers and intermittent intravenous prostacyclin analogues.3,4 However, there is a need to identify oral therapies that are more efficacious than those currently available. Objectives To determine the activity of selexipag, an oral, selective, prostacyclin receptor agonist, on RP attack frequency in pts with SSc. Methods The study comprised a placebo single-blind run-in phase of 2–4-weeks followed by an …

030203 arthritis & rheumatologymedicine.medical_specialtyFuture studiesStudy drugbusiness.industryImmunologyPhases of clinical researchCondition scoreSelexipagPlaceboGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compoundSafety profile0302 clinical medicineRheumatologychemistryInternal medicinemedicineImmunology and Allergy030212 general & internal medicinebusinessAdverse effectAnnals of the Rheumatic Diseases
researchProduct

Acceptance and Commitment Therapy for Health Behavior Change: A Contextually-Driven Approach.

2018

Promoting health behavior change presents an important challenge to theory and research in the field of health psychology. In this paper, we introduce a context-driven approach, the Acceptance and Commitment Therapy (ACT) model which is built on Relational Frame Theory. The ACT-based intervention aims to promote individuals’ new health behavior patterns through the improvement of the key construct of psychological flexibility, which is defined as the ability to contact the present moment more fully with acceptance and mindfulness as a conscious human being. Building on the psychological flexibility model, implemented through the six core ACT processes, individuals improve maintenance of lon…

050103 clinical psychologybehavior changeterveyspsykologiaMindfulness6.6 Psychological and behaviouralMini Reviewbehavior maintenancehyväksymis- ja omistautumisterapialcsh:BF1-990Basic Behavioral and Social ScienceAcceptance and commitment therapyRelational frame theorypsychological flexibility03 medical and health sciences0302 clinical medicineClinical ResearchIntervention (counseling)Behavioral and Social SciencePsychology0501 psychology and cognitive sciencesta515General Psychology05 social sciencesBehavior changeEvaluation of treatments and therapeutic interventionsFlexibility (personality)ta3141ACTHealth psychologyMental HealthGood Health and Well Beinglcsh:Psychologyrelational frame theoryterveyskäyttäytyminenCognitive SciencesPsychologyConstruct (philosophy)Mind and BodySocial psychology030217 neurology & neurosurgery
researchProduct

Trajectories of stress biomarkers and anxious-depressive symptoms from pregnancy to postpartum period in women with a trauma history

2019

Background: Cross-sectional studies have found that a trauma history can be associated with anxious-depressive symptomatology and physiological stress dysregulation in pregnant women. Methods: This prospective study examines the trajectories of both anxiety and depressive symptoms and salivary cortisol and alpha-amylase biomarkers from women with (n = 42) and without (n = 59) a trauma history at (i) 38th week of gestation (T1), (ii) 48 hours after birth (T2), and (iii) three months after birth (T3). Results: The quantile regression model showed that trauma history was associated with higher cortisol levels at T1 and this difference was sustained along T2 and T3. Conversely, there were no si…

050103 clinical psychologyembarazolcsh:RC435-571depresión抑郁Trauma怀孕Ansiedad03 medical and health sciences0302 clinical medicinelcsh:Psychiatrystress biomarkersmedicine0501 psychology and cognitive sciencespostpartum• Follow-up study on pregnant women with a trauma history. •Data analysed by quantile and ordinal regression models.•Trauma history and high cortisol levels from pregnancy to postpartum. • High α-amylase levels during postpartum period regardless of a trauma history. • Trauma history and high anxious symptoms from late pregnancy to childbirth.Physiological stressDepression (differential diagnoses)Depressive symptoms产后Clinical Research ArticlePregnancybiomarcadores de estrésbusiness.industryfungi05 social sciences焦虑food and beveragesanxietymedicine.diseasepostparto030227 psychiatrytraumaStress biomarkersdepressionAnxietypregnancymedicine.symptombusiness创伤Postpartum period应激生物标志物Clinical psychologyEuropean Journal of Psychotraumatology
researchProduct

Feasibility of a Responsibility-Based Leadership Training Program for Novice Physical Activity Instructors

2021

Most coaches and instructors would like to teach more than just sport skills to their athletes and children. However, to promote athletes' or children's holistic development and teach them to take responsibility and lead, requires the coaches and instructors to first master the skills themselves. Therefore, feasible, high quality leadership training programs where coaches and physical activity instructors are taught to teach and share leadership are needed. The aim of the current study was to evaluate the feasibility of a leadership training program to optimize it and to determine whether to proceed with its evaluation. In the leadership training program, eight Finnish novice physical activ…

AFTER-SCHOOL PROGRAMliikunnanohjaajat515 PsychologySOCIAL-RESPONSIBILITYvastuullisuusIMPLEMENTATION FIDELITYphysical activitykoulutusohjelmatBasic Behavioral and Social ScienceSPORTshared leadershipClinical ResearchBehavioral and Social ScienceADOLESCENTSPsychologyEDUCATION TEACHERSteaching personal and social responsibility modeljohtajuusOriginal Researchpositive youth developmentleadership trainingRANDOMIZATIONSHARED LEADERSHIPMODEL5144 Social psychologyammatillinen kehitys5141 Sociology516 Educational sciencesCognitive Sciencesnovice instructorPOSITIVE YOUTH DEVELOPMENTfeasibility
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Total energy expenditure is repeatable in adults but not associated with short-term changes in body composition

2022

Low total energy expenditure (TEE, MJ/d) has been a hypothesized risk factor for weight gain, but repeatability of TEE, a critical variable in longitudinal studies of energy balance, is understudied. We examine repeated doubly labeled water (DLW) measurements of TEE in 348 adults and 47 children from the IAEA DLW Database (mean ± SD time interval: 1.9 ± 2.9 y) to assess repeatability of TEE, and to examine if TEE adjusted for age, sex, fat-free mass, and fat mass is associated with changes in weight or body composition. Here, we report that repeatability of TEE is high for adults, but not children. Bivariate Bayesian mixed models show no among or within-individual correlation between body c…

Adipose Tissue/metabolismAdultMaleDatabases FactualBody Composition/physiologyScienceGeneral Physics and AstronomyWeight GainArticleGeneral Biochemistry Genetics and Molecular BiologyEnergy Metabolism/physiologyRC1200DatabasesClinical Research2.1 Biological and endogenous factorsHumansVDP::Medisinske Fag: 700ObesityLongitudinal StudiesAetiologyChildMetabolic and endocrineFactualWeight Gain/physiologyNutritionPediatricMultidisciplinaryWater/metabolismQWaterBayes TheoremGeneral ChemistryMiddle AgedRisk factorsAdipose TissueIsotope LabelingBody CompositionFemaleIAEA DLW Database ConsortiumEnergy Metabolismhuman activities
researchProduct

Physical activity and fat-free mass during growth and in later life.

2021

ABSTRACT Background Physical activity may be a way to increase and maintain fat-free mass (FFM) in later life, similar to the prevention of fractures by increasing peak bone mass. Objectives A study is presented of the association between FFM and physical activity in relation to age. Methods In a cross-sectional study, FFM was analyzed in relation to physical activity in a large participant group as compiled in the International Atomic Energy Agency Doubly Labeled Water database. The database included 2000 participants, age 3–96 y, with measurements of total energy expenditure (TEE) and resting energy expenditure (REE) to allow calculation of physical activity level (PAL = TEE/REE), and cal…

Adipose Tissue/metabolismMaleAgingIMPACTMedicine (miscellaneous)Medical and Health SciencesLONGITUDINAL CHANGESRC12000302 clinical medicineEngineeringenergy expenditureFaculty of Science80 and overMedicineWATER030212 general & internal medicineChildInternational Atomic Energy Agency Doubly Labeled Water database groupAged 80 and overNutrition and DieteticsMiddle Aged3142 Public health care science environmental and occupational healthEditorialAdipose TissueChild PreschoolFemalephysical activity levelPeak bone massAdultAdolescentPhysical activityBONE MASS030209 endocrinology & metabolismDoubly labeled waterFat massVDP::Medisinske Fag: 700::Helsefag: 800::Ernæring: 81103 medical and health sciencesYoung AdultAnimal scienceTotal energy expenditureFat free massClinical ResearchBENEFITSHumansResting energy expenditure/dk/atira/pure/core/keywords/TheFacultyOfSciencePreschoolExerciseNutritionAgedbody compositionNutrition & DieteticsAdipose Tissue/metabolism; Adolescent; Adult; Aged; Aged 80 and over; Body Composition; Child; Child Preschool; Cross-Sectional Studies; Energy Metabolism; Exercise; Female; Humans; Male; Middle Aged; Young Adult; age; body composition; doubly labeled water; energy expenditure; physical activity levelbusiness.industryPreventionPhysical activity leveldoubly labeled water3141 Health care scienceCross-Sectional StudiesageLEAN BODY-MASSYOUNGWEIGHTbusinessEnergy Metabolismhuman activities
researchProduct

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Canc…

2018

AbstractPurpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer.Patients and Methods: Patients received 6-mg oral taselisib capsules daily plus intramuscular fulvestrant (500 mg) until disease progression or unacceptable toxicity. Tumor tissue (if available) was centrally evaluated for PIK3CA mutations. Adverse events (AE) were recorded using NCI-CTCAE v4.0. Tumor response was investigator-determined using RECIST v1.1.Results: Median treatment duration was 4.6 (range: 0.9–40.5) months. All patients expe…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Phases of clinical researchBreast NeoplasmsDisease-Free SurvivalArticle03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectFulvestrantAgedAged 80 and overResponse rate (survey)Fulvestrantbusiness.industryImidazolesCancerMiddle Agedmedicine.diseaseOxazepines030104 developmental biologyReceptors EstrogenOncologyHormone receptor030220 oncology & carcinogenesisMutationToxicityFemalebusinessmedicine.drugClinical Cancer Research
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

Cyclophosphamide plus Epidoxorubicin and 5-Fluorouracil with Folinic Acid as a Novel Treatment in Metastatic Breast Cancer: Preliminary Results of a …

1991

Twenty consecutive patients with advanced breast cancer were treated with a combination of cyclophosphamide 600 mg/m2 i.v. on day 1, epidoxorubicin 75 mg/m2 on day 1, and 5-fluorouracil 375 mg/m2 i.v. with folinic acid 200 mg/m2 i.v. on days 1----3. The overall response rate was 60%, with 10% of patients showing a complete response with a mean duration of 11.1 + months, and 50% of patients a partial response of 7.4 + months. A stabilization of 5.2 + months was obtained in 20% of cases, while 20% of patients progressed. The most frequently observed toxicity was leukopenia, while expected mucosal toxicities were rather mild.

Adult0301 basic medicinemedicine.medical_specialtyCyclophosphamide030106 microbiologyLeucovorinPhases of clinical researchBreast NeoplasmsGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideEpirubicinPharmacologyLeukopeniabusiness.industryRemission InductionCancerMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisDrug EvaluationFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct